Clinical Trial Update: The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing oral nanocurcumin's immunomodulatory effects in multiple sclerosis patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• nanocurcumin (oral) (curcumin nanoparticle formulation)

Snippet

Sponsor: Tabriz University of Medical Sciences | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED